Fact CheckerSign in

NCT03671889Recruiting

ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease

Assessment of Safety and Efficacy of ExAblate Blood-Brain Barrier Disruption for the Treatment of Patients With Probable Alzheimer's Disease

Source: ClinicalTrials.gov · Last updated 9 Jan 2026

Brief summary (registry, in English)

The purpose of this study is to evaluate the safety and efficacy of the ExAblate Model 4000 Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable Alzheimer's Disease (AD).

Status (registry)
Recruiting
Study type
Interventional
Enrollment
50 (estimated)
First submitted
3 Aug 2018
Start date
28 Sept 2018
Primary completion date
31 Jan 2028
Lead sponsor
InSightec
NCT number
NCT03671889

What you commit to

  • Study type: Interventional
  • Planned participants: 50
  • From 28 Sept 2018 to the primary completion date, 31 Jan 2028
  • 10 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Currently in a clinical trial involving an investigational product or non-approved use of a drug or device or in any other type of medical research

Other illness

  • Significant cardiac disease or unstable hemodynamic status
  • History of a bleeding disorder
  • History of liver disease
  • History of seizure disorder or epilepsy
  • Chronic pulmonary disorders
  • Positive human immunodeficiency virus (HIV)

Other

  • MRI Findings
  • Presence of unknown or MR unsafe devices anywhere in the body
  • Relative contraindications to ultrasound contrast agent or PET amyloid tracer
  • Known cerebral or systemic vasculopathy
  • Significant depression and at potential risk of suicide
  • Any contraindications to MRI scanning
  • Any contraindication to lumbar puncture for collection of cerebral spinal fluid
  • Untreated, uncontrolled sleep apnea
  • Severely Impaired renal function
  • Known apolipoprotein E allele (ApoE4) homozygosity

Who the study is looking for

  • Male or Female between 50-85 years of age
  • Probable Alzheimer's Disease (AD)
  • If taking concurrent Alzheimer's medication, has been on the medication for at least 2 months with a stable dose for at least 3 months
  • Able to communicate sensations during the ExAblate MRgFUS procedure
  • Ambulatory

Age in the registry: 50 years to 85 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (10)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
The Ohio State University -Wexner Medical Center
Coordinator of this site? Confirm its status
ColumbusUnited StatesActive, not recruiting
University of Texas Southwestern Medical Center
Coordinator of this site? Confirm its status
DallasUnited StatesActive, not recruiting
Delray Medical Center & Florida Atlantic University
Coordinator of this site? Confirm its status
Delray BeachUnited StatesRecruiting
Broward Health Medical Center & The University of Florida
Coordinator of this site? Confirm its status
Fort LauderdaleUnited StatesRecruiting
University of Florida Health Shands
Coordinator of this site? Confirm its status
GainesvilleUnited StatesRecruiting
Baptist Health South Florida & Florida International University
Coordinator of this site? Confirm its status
MiamiUnited StatesRecruiting
West Virginia University Rockefeller Neuroscience Center
Coordinator of this site? Confirm its status
MorgantownUnited StatesActive, not recruiting
Weill Cornell Medicine
Coordinator of this site? Confirm its status
New YorkUnited StatesActive, not recruiting
Advent Health
Coordinator of this site? Confirm its status
OrlandoUnited StatesRecruiting
Tampa General Hospital
Coordinator of this site? Confirm its status
TampaUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.